1-7 QUALITATIVE RESEARCH FOR OSTEOARTHRITIS: BETTER UNDERSTAND PATIENTS AND CARE PROVIDERS VIEWS AND NEEDS TO IMPROVE MANAGEMENT STRATEGIES  by Poiraudeau, S.
S2 Abstracts from Invited Speakers / Osteoarthritis and Cartilage 19S1 (2011) S1–S6
The stimulus-response approach offers the opportunity to increase the
accuracy and sensitivity in detecting underlying pathologies that can
be elevated in response to speciﬁc provocative stimuli. This type of
stimulus-model response model offers a valuable opportunity to probe
the in vivo systems response of osteoarthritis as a framework for the
early detection and treatment evaluation.
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SYSTEMS BIOLOGY: BRIDGING THE GAP BETWEEN MOLECULES,
ANIMAL MODELS AND OA PATIENTS
W.L. Stanford. Ottawa Hosp. Res. Inst., Ottawa, ON, Canada
OA is a complex disease in which many determinants underlie both
the etiology and progression. While reductionist studies have identiﬁed
many of the molecules and environmental factors involved in OA, the
ﬁeld, and thus patients, could beneﬁt from a more comprehensive
systems biology approach. Systems biology seeks to answer biological
questions by mathematically modeling the entire system of relevant
genes, proteins, cells and other factors. To generate models, various
“omics” technologies are applied to generate a comprehensive landscape
of the DNA, RNA, protein expression and metabolic state of the cell and/or
tissue. Until recently, this approach has relied mainly on simple genetic
models, but the invention of induced pluripotent stem cells (iPSCs)
has opened up exciting new avenues for the ﬁeld. iPSCs are powerful
embryonic-like stem cells which can be derived from adult blood or
skin cells, through genetic reprogramming. iPSCs can be differentiated
into many kinds of specialized cells in the laboratory, including cells
that are relevant to OA, such as chondrocytes. Using systems biology to
study iPSC-derived chondrocytes from multiple OA patients may allow us
to identify patient subpopulations with discrete underlying biochemical
networks driving the progression of their disease. This approach could
usher in a new generation of personalized OA therapies that target the
biochemical networks that are disrupted in individual patients.
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CELL THERAPY OPTIONS FOR OSTEOARTHRITIS: STEM/PROGENITOR
CELL
A. Reddi. Univ. of California, Davis, Sacramento, CA, USA
The aim of this workshop is to convey in an interactive session the current
excitement in the area of Stem / Progenitor Cells for potential therapeutic
options for osteoarthritis. Morphogenesis is the developmental cascade
of pattern formation and establishment of the body plan including the
bilateral symmetry of the adult form. Regenerative medicine and Tissue
Engineering endeavors to design and restore function to lost or damaged
parts due to diseases like arthritis and trauma. The three key elements for
tissue regeneration of damaged articular cartilage in synovial joints are
signals including morphogens such as BMPs, responding stem cells and
a scaffold of extracellular matrix. The discussion of this research area
will begin with a presentation by Robert Sah, UCSD on challenges in
design, fabrication and functional evaluation of synovial joints. This will
be followed by Farshid Guilak, from Duke University on Adipose-derived
stem cells for cartilage differentiation. The directed differentiation of
adult and embryonic stem cells into articular cartilage will be presented
by A. Hari Reddi. The BMPs are lineage directing morphogens that are
critical for chondrogenesis. The adult progenitors and stem cells for
chondrogenesis are present in synovium, bone marrow, adipose tissue
and muscle. The open general discussion will be mutually beneﬁcial and
audience participation is strongly encouraged.
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INFLAMMATION AND IMMUNITY IN OA
R. Liu-Bryan. VAMC Med.-Rheumatology, UCSD, San Diego, CA, USA
Articular cartilage degeneration is a major characteristic of OA. Changes
in other joint tissues including subchondral bone and synovium are often
associated with OA. It is now accepted that inﬂammation is involved in
the development and progression of OA in both early and late stages of
the disease. Secreted inﬂammatory mediators such as proinﬂammatory
cytokines, particularly IL-1b and TNFa, are major players in degeneration
of articular cartilage matrix. IL-1b and TNFa, produced mainly by
activated synoviocytes, mononuclear cells and chondrocytes, down-
regulate the synthesis of major extracellular matrix components (ECM)
by inhibiting anabolic activity of chondrocytes, and enhance matrix
catabolism by stimulating chondrocytes to release several proteolytic
enzymes. In addition, IL-1b and TNFa stimulate articular cells to produce
a number of inﬂammatory mediators including cytokine IL-6 and
chemokine IL-8, nitric oxide (NO) and prostaglandin E2 (PGE2), all of
which have been implicated in OA pathology.
Inﬂammation in OA is partly secondary to cartilage and other articular
joint tissue damage. Innate immune responses to endogenous danger
signals or alarmins (danger-associated molecular patterns (DAMPs)) that
are derived from damaged articular joint tissues such as low molecular
weight hyaluronan (LMW-HA), high mobility group box chromosomal
protein 1 (HMGB-1), and members of S100/calgranulin family of
proteins are implicated in OA progression by induction of inﬂammatory
mediators. Toll-like receptor (TLR) and receptor for advanced glycation
end products (RAGE) signaling can transduce response to these signals
and some of these signals (HMGB1, S100A8) activate both of these
receptors.
Recent studies demonstrated that activity of AMP-activated protein
kinase (AMPK), a master regulator of cell energy homeostasis and
metabolism, is decreased in OA cartilage and in chondrocytes following
treatment with IL-1b or TNFa. AMPK pharmacological activators
attenuate dephosphorylation of AMPKa and pro-catabolic responses
in chondrocytes induced by these cytokines. These results suggest
that maintenance of AMPK activity supports cartilage homeostasis by
protecting cartilage matrix from inﬂammation-induced degradation.
Further investigation and new therapeutic approaches are needed.
New targets that encompass innate immune receptor-mediated
signaling, cytokine activity, chondrocyte metabolism, matrix anabolism
and catabolism have potential to prevent and therapeutically slow
development and progression of OA.
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QUALITATIVE RESEARCH FOR OSTEOARTHRITIS: BETTER
UNDERSTAND PATIENTS AND CARE PROVIDERS VIEWS AND NEEDS
TO IMPROVE MANAGEMENT STRATEGIES
S. Poiraudeau. AP-HP, Universite´ Paris Descartes, Paris, France
The patient point of view regarding health status has gained importance
in decision-making procedures and has been considered a possible
criterion standard to assess treatment efﬁcacy. However, disability and
Health-related quality of life are usually recorded using pre-ﬁxed item
questionnaires that do not take into account patients priorities. Patients
with knee or hip osteoarthritis (OA) and their physician opinions differ
on the importance of disabilities. Patients perceive knee OA to be
more disabling than hypertension, diabetes mellitus and heart diseases
whereas physicians consider these three latter conditions the most
important chronic conditions. These discrepancies between patients
and physicians in deﬁning the importance of an illness should lead
to a paradigmal shift toward more patient-centered approaches. Taking
into account patients priorities may lead to a better understanding of
what is important to them and therefore to propose more individualized
management strategies with increased compliance and efﬁcacy.
Although patients with knee and hip OA and their physicians may
differ in their assessment in health and symptoms status, views of
patients and practitioners have been seldom studied. Qualitative research
is probably the best way to understand patients’ needs and contexts
and could improve therapeutic strategies and their assessment. The US
Food and Drugs administration has recently proposed guidelines for
patient-reported outcomes that emphazise the need for semi-structured
interviews of patients to ensure content validity of these instruments.
Semi-structured interviews and/or focus groups are widely used methods
to constitute qualitative data base and these approaches are of particular
interest in chronic conditions. A qualitative study involving semi-
structured interviews of German patients with OA, nurses, and general
practitioners (GPs) suggested that GPs should focus more on pain and
disability and on giving more information about treatments. Using the
same techniques, we recently reported data suggesting several ways
to improve the patient-practitioner relationship and the efﬁcacy of
treatment strategies, probably by increasing their acceptability and
compliance. The main factors of improvement we identiﬁed are providing
adapted, formalized information to patients, adopting more global
assessment and therapeutic approaches, and dealing more accurately
with patients’ paradoxal representation of drug therapy. We also
conﬁrmed that patients’ and practitioners’ views largely differ, and
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more attention should be paid to patients’ views to increase treatment
adherence.
Qualitative studies have also permitted to better understand differences
in access to total knee or hip arthroplasties among patients with knee
or hip OA and motives of satisfaction or dissatisfaction of patients after
these surgical interventions.
Finally, qualitative research will probably lead to consider concepts
differing from disability or HRQoL such as expectations, needs, fears
and beliefs and help to develop accurate measure tools to assess these
concepts.
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THE ROLE OF MIR-140 IN OA PATHOGENESIS
H. Asahara1,2. 1The Scripps Res. Inst., La Jolla, CA, USA; 2Tokyo Med. and
Dental Univ. and Natl. Res. Inst. for Child Hlth.and Dev., Tokyo, Japan
Purpose: Osteoarthritis (OA) is the most prevalent disorder of synovial
joints, characterized by focal areas of articular cartilage destruction.
MicroRNAs (miRNAs) are a family of ~22-nucleotide (nt) noncoding
RNAs that are evolutionarily conserved and regulate gene expression
by posttranscriptional mechanisms. miR-140 is highly expressed in
chondrocytes, however its function has not yet been elucidated.
Methods and Results: To examine the role of miR140 in vivo, we
generated miR140 null mice. During embryogenesis and at neonatal
stage, skeletal formation of miR140 null mice is not signiﬁcantly
disturbed compared with wild type mice. Postnatal growth of limbs
and body of null mice is slightly signiﬁcantly repressed compared with
wild-type.
In null miR140 mice knee articular cartilage we observed spontaneous
onset of osteoarthritis at the age of 8 months.
To test the function of miR-140 in articular cartilage, we performed
microarray for mRNA expression with articular cartilage from wild
type and miR-140 null mice and on chondrocytes transfected with
miR-140. Among the mRNAs most highly increased in miR140
null mice was ADAMTS-5, a critical cartilage degradation enzyme
in osteoarthritis pathogenesis. ADAMTS-5 is also a strong miR-140
candidate as predicted from Target scan bioinformatics data-base.
ADAMTS-5 expression is signiﬁcantly increased in chondrocytes from
miR-140 null mice. Consistent with this, GAG loss in articular cartilage
was signiﬁcantly increased in miR140 null mice. Overexpression of miR-
140 in chondrocytes from miR-140 null mice decreased the expression of
ADAMTS-5. Furthermore, reporter construct carrying ADAMTS-5 3’ UTR
was also inhibited by miR-140 overexpression.
Conclusions: These data indicate that ADAMTS-5 is directly inhibited
by miR-140 and that loss of miR-140 causes catabolic effect on cartilage
homeostasis and subsequent osteoarthritis, at least in part, via regulating
ADAMTS-5.
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HAND OA: A DISEASE IN NEED OF TREATMENT
K. Dziedzic. Arthritis Res. UK Primary Care Ctr. Keele Univ., Keele, United
Kingdom
Hand osteoarthritis is one of the commonest forms of osteoarthritis and
until recent years there has been limited research and a general feeling
that nothing can be done for people with hand OA. The talk will have
an emphasis on primary care where most people present and where
there is a gap between what patients could be offered and what patients
receive [1].
The presentation will describe hand OA not as a single disease but as
a group of complex conditions [2] ranging a syndrome of joint pain
accompanied by functional limitation, or a condition deﬁned by the
presence of features and severity of symptoms (ACR criteria) [3], to highly
characterised subsets of radiographic hand OA [4]. The presentation
in particular will draw on ﬁndings from three large cohorts of adults
50 years and over studied in the North West Midlands in the UK
(n =30,000) (Norstop1 [5], CAS-HA [6], Smooth [7]).
The prevalence of hand OA and impact on hand pain and functional
decline over three years will be described, along with consultation
for hand pain and hand OA in primary care using survey data and
consultation records. Hand OA as an important marker of OA in the
person will be highlighted.
Using OARSI recommendations for the design and conduct of trials in
hand OA [8] patients in need of treatment will be deﬁned and the uptake
of treatment by eligible individuals will be reported using a study of hand
exercises and joint protection as an example [7].
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WHAT’S WRONG WITH ANIMAL MODELS OF PAIN?
J. Mogil. McGill Univ., Montreal, QC, Canada
Recent decades have seen an explosion in our understanding of the
molecular and cellular underpinnings of pain, but virtually none of this
knowledge has resulted in new clinical therapies. Many pain researchers
believe that the problem may lie in the existing animal models of pain,
which are reliable but much more complex and subtle than is commonly
realized, and of questionable clinical relevance. Most basic science studies
of pain continue to rely on the measurement of reﬂexive, evoked
hypersensitivity responses after artiﬁcial neuropathic or inﬂammatory
injuries, whereas clinical pain in humans features much spontaneous
pain and an important cognitive and emotional overlay. In addition
to the disconnect between clinical symptoms and animal measures,
there is a disconnect between the clinical epidemiology of pain and the
types of pain being modeled in animals. We have recently attempted
to develop an “ethological” approach to animal models of common pain
pathologies, involving systematic and rigorous analysis of videotaped
spontaneous mouse behaviors. I will talk about some recent successes in
our laboratory, involving migraine, vestibulodynia, and the development
of a facial expression-based pain scale for the mouse.
